Colin J. Meyer
2021
In 2021, Colin J. Meyer earned a total compensation of $2.6M as Chief Innovation Officer and Executive Vice President at REATA PHARMACEUTICALS, a 39% decrease compared to previous year.
Compensation breakdown
| Bonus | $202,500 |
|---|---|
| Option Awards | $1,823,878 |
| Salary | $540,000 |
| Total | $2,566,378 |
Meyer received $1.8M in option awards, accounting for 71% of the total pay in 2021.
Meyer also received $202.5K in bonus and $540K in salary.
Rankings
In 2021, Colin J. Meyer's compensation ranked 5,053rd out of 12,415 executives tracked by ExecPay. In other words, Meyer earned more than 59.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,053 out of 12,415 | 59th |
Division Manufacturing | 2,127 out of 5,505 | 61st |
Major group Chemicals And Allied Products | 911 out of 2,375 | 62nd |
Industry group Drugs | 815 out of 2,096 | 61st |
Industry Pharmaceutical Preparations | 583 out of 1,546 | 62nd |
Pay ratio
| Colin J. Meyer's Pay | $2,566,378 |
|---|---|
| Median Employee's Pay | $244,581 |
| Pay Ratio | 10to 1 |
In 2021, the annual total compensation of Colin J. Meyer was $2,566,378.
The annual total compensation of the median employee at REATA PHARMACEUTICALS was $244,581.
The ratio of Colin J. Meyer's pay to the pay of median employee was therefore 10 to one.
Source: SEC filing on April 29, 2022.
Meyer's colleagues
We found four more compensation records of executives who worked with Colin J. Meyer at REATA PHARMACEUTICALS in 2021.
News
REATA PHARMACEUTICALS CEO J Huff's 2021 pay falls 37% to $4M
April 29, 2022
REATA PHARMACEUTICALS CEO J Huff's 2020 pay rises 15% to $6.4M
April 30, 2021
REATA PHARMACEUTICALS CFO Manmeet Soni receives $13M in 2019
April 29, 2020
REATA PHARMACEUTICALS CEO J Huff's 2018 pay falls 82% to $935K
April 30, 2019